Pacira Pharmaceuticals (PCRX) AI Stock Analysis

• Market Cap: $981.78M
• Dividend Yield: N/A
• Average Volume (3M): 564.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: 3.14%
• EPS Growth: N/A
• Country: US
• Employees: 788
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.70
• Shares Outstanding: 44,932,720
• 10 Day Avg. Volume: 629,963
• 30 Day Avg. Volume: 564,800
• PEG Ratio: 0.03
• Price to Book (P/B): 1.12
• Price to Sales (P/S): 1.24
• P/FCF Ratio: 4.87
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: $26.00 ▲(18.99% Upside)

Pacira Pharmaceuticals' overall stock score is driven by its stable financial performance and positive earnings call highlights, including strong revenue growth and strategic initiatives. However, the stock's high valuation and technical indicators suggest caution, as it appears overvalued and shows signs of weak momentum.

Positive Factors

Revenue Growth

Consistent revenue growth, particularly from core products like EXPAREL, indicates strong market demand and positions Pacira for continued expansion.

Pipeline Expansion

Expanding the product pipeline with innovative formulations like AMT-143 enhances long-term growth prospects and strengthens competitive positioning.

Cash Flow and Shareholder Returns

Strong cash flow and strategic share repurchases reflect financial health and commitment to shareholder value, supporting sustainable growth.

Negative Factors

Zilretta Sales

Sluggish sales of Zilretta indicate challenges in market penetration and could impact overall revenue growth if not addressed.

GPO Discount Impact

Higher-than-expected discounting pressures from GPO agreements may compress margins, affecting profitability and pricing strategy.

Elective Procedure Market

Sluggish growth in elective procedures could limit demand for Pacira's products, impacting revenue potential in a key market segment.

Pacira Pharmaceuticals Business Overview & Revenue Model

Company Description

Pacira Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative non-opioid pain management solutions. The company operates primarily in the pharmaceutical sector, with a strong emphasis on improving patient outcomes in surgical and non-surgical settings. Pacira's core product, EXPAREL, is a liposomal formulation of bupivacaine designed to provide prolonged local analgesia and reduce the need for opioids post-surgery. The company is dedicated to enhancing the way pain is managed and is committed to advancing its pipeline of products aimed at improving recovery and patient experiences in various surgical procedures.

How the Company Makes Money

Pacira Pharmaceuticals generates revenue primarily through the sales of its flagship product, EXPAREL, which is marketed to hospitals, surgical centers, and healthcare providers. The company also earns revenue from collaborations and partnerships with other pharmaceutical firms, which may include licensing agreements or co-development arrangements for its pipeline products. Additionally, Pacira may benefit from government reimbursements and healthcare insurance payments for its products, which are crucial for driving sales and expanding market access. The company has strategically focused on building relationships with healthcare professionals and institutions to promote the adoption of non-opioid pain management solutions, contributing to its overall revenue growth.

Pacira Pharmaceuticals Financial Statement Overview

Summary

Pacira Pharmaceuticals exhibits stable financial health with consistent revenue growth and improved operational efficiency. The company has effectively managed its debt, enhancing its financial stability. Cash flow generation remains strong, supporting future growth opportunities. However, profitability margins could be improved to enhance shareholder value.

Income Statement

Pacira Pharmaceuticals shows a modest revenue growth rate of 1.55% TTM, with a stable gross profit margin of 58.9%. However, the net profit margin is relatively low at 4.13%, indicating limited profitability. The EBIT and EBITDA margins have improved over the previous year, suggesting better operational efficiency.

Balance Sheet

The company has significantly reduced its debt-to-equity ratio to 0.013 TTM, indicating strong financial stability. The return on equity is modest at 3.87%, reflecting moderate profitability. The equity ratio is healthy, showing a solid capital structure.

Cash Flow

Pacira Pharmaceuticals has achieved a free cash flow growth rate of 6.1% TTM, demonstrating strong cash generation capabilities. The operating cash flow to net income ratio is robust at 1.32, indicating efficient cash conversion. The free cash flow to net income ratio is also strong at 0.88.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	716.79M	700.97M	674.98M	666.82M	541.53M	429.65M
Gross Profit	567.46M	530.54M	490.31M	467.53M	401.28M	312.32M
EBITDA	147.82M	29.12M	154.59M	140.38M	113.95M	63.51M
Net Income	21.44M	-99.56M	41.95M	15.91M	41.98M	145.52M
Balance Sheet
Total Assets	1.30B	1.55B	1.57B	1.68B	2.08B	1.27B
Cash, Cash Equivalents and Short-Term Investments	246.33M	484.62M	278.58M	288.65M	656.41M	521.66M
Total Debt	425.31M	638.85M	586.04M	763.39M	1.13B	541.13M
Total Liabilities	570.36M	775.17M	704.26M	906.19M	1.34B	654.83M
Stockholders Equity	727.21M	778.35M	870.13M	775.01M	730.41M	619.69M
Cash Flow
Free Cash Flow	124.20M	178.75M	139.49M	115.20M	79.85M	39.23M
Operating Cash Flow	141.44M	189.39M	154.65M	145.27M	125.72M	77.03M
Investing Cash Flow	79.78M	-83.28M	77.54M	-225.19M	-20.79M	-277.61M
Financing Cash Flow	-319.93M	17.36M	-183.03M	-401.53M	380.69M	222.30M

Pacira Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 21.85
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCRX, the sentiment is Positive. The current price of 21.85 is below the 20-day moving average (MA) of 22.97, below the 50-day MA of 23.44, and below the 200-day MA of 24.40, indicating a neutral trend. The MACD of 0.15 indicates Negative momentum. The RSI at 55.47 is Neutral, neither overbought nor oversold. The STOCH value of 40.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PCRX.

Pacira Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	76 Outperform	$1.26B	12.13	14.84%	―	-0.03%	-27.66%
COLL	70 Neutral	$1.46B	28.77	22.96%	―	26.34%	-32.79%
PCRX	69 Neutral	$981.78M	―	2.90%	―	3.14%	―
ANIP	64 Neutral	$1.90B	51.74	7.83%	―	48.87%	―
AVDL	57 Neutral	$2.09B	―	-0.32%	―	79.88%	99.60%
SUPN	55 Neutral	$2.65B	―	-1.86%	―	4.54%	-130.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Pacira Pharmaceuticals Corporate Events

Pacira BioSciences Reports Strong Q3 Growth Amid Challenges

Pacira BioSciences’ recent earnings call conveyed a generally positive sentiment, highlighting robust revenue growth and improved manufacturing efficiencies. The company also shared exciting developments in its clinical pipeline. However, the call was not without its challenges, as slower-than-expected sales growth for Zilretta and pricing impacts from new GPO agreements were noted. Additionally, the growth in the elective procedure market was described as sluggish.

Pacira BioSciences Reports Strong Q3 2025 Results

Pacira BioSciences, Inc., a leader in non-opioid pain management therapies, reported its financial results for the third quarter of 2025, showcasing a steady performance in its innovative healthcare solutions sector. The company, known for its flagship products like EXPAREL, ZILRETTA, and iovera°, continues to focus on transforming patient care through advanced pain management solutions.

Pacira’s Pediatric Analgesia Study: A Potential Game-Changer for Postoperative Pain Management

Pacira Pharmaceuticals is conducting a study titled ‘A Multicenter, Open-label, Randomized, Bupivacaine-Controlled Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Aged 0 to Less Than 6 Years Undergoing Cardiac Surgery.’ The study aims to assess the pharmacokinetics and safety of EXPAREL, a local infiltration analgesic, compared to bupivacaine in young pediatric patients post-cardiac surgery. This research is significant as it explores pain management solutions for a vulnerable age group.

Pacira’s Innovative Study on Knee OA Pain Management: What Investors Need to Know

Study Overview: Pacira Pharmaceuticals is conducting a study titled ‘Innovations in Genicular Outcomes Registry’ to gather prospective data on pain management for chronic knee osteoarthritis (OA) and pain optimization for knee arthroplasty due to OA. This research is significant as it aims to improve treatment outcomes for patients suffering from knee OA, a common and debilitating condition.

Pacira’s Phase 2 Study: A New Approach to Hip Osteoarthritis Treatment

Pacira Pharmaceuticals is conducting a Phase 2 clinical study titled ‘A Phase 2, Randomized, Open-Label, Two-Arm Study to Evaluate a Procedure for Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release (TCA-IR) in Subjects With Osteoarthritis of the Hip.’ The study aims to assess the effectiveness of an injection procedure using two different needle sizes in patients with hip osteoarthritis, highlighting its potential significance in improving treatment outcomes.

Pacira’s New Osteoarthritis Treatment: A Promising Clinical Study Update

Pacira Pharmaceuticals is conducting a Phase 2 clinical study titled ‘A Phase 2, Two-Part, Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Tolerability of Enekinragene Inzadenovec (PCRX-201) in Subjects With Painful Osteoarthritis of the Knee.’ The study aims to evaluate the safety and tolerability of PCRX-201, a potential treatment for knee osteoarthritis, in patients aged 45 to 80. This research is significant as it explores a new therapeutic option for managing osteoarthritis pain.

Pacira’s ZILRETTA Study: A Potential Game-Changer for Osteoarthritis Pain Management

Pacira Pharmaceuticals, Inc. is currently recruiting for a Phase 3 clinical study titled ‘A Study to Evaluate the Efficacy and Safety of ZILRETTA in Subjects With Glenohumeral Osteoarthritis.’ The primary objective is to assess the efficacy of ZILRETTA on pain relief following an intra-articular injection compared to a normal saline placebo. Secondary objectives include comparing ZILRETTA’s efficacy to triamcinolone acetonide injectable suspension (TCA-IR) and evaluating its safety.

Pacira’s Promising Study on Iovera° System for Spasticity: A Potential Game-Changer

Study Overview: Pacira Pharmaceuticals is conducting a multicenter, randomized, double-blind, sham-controlled study titled ‘A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity.’ The study aims to evaluate the efficacy and safety of the iovera° system in treating upper extremity spasticity, a condition often associated with cerebral or spinal issues. This study is significant as it could offer a new treatment option for patients suffering from this debilitating condition.